文献速递神经肌肉病

眼肌型重症肌无力评定量表问卷的多中心验证

Multicenter Validation of the Ocular Myasthenia Gravis Rating Scale Questionnaire.
PubMed 文献 · Neurology · 2024-12-10

本研究在3个医疗中心前瞻性纳入134例眼肌型重症肌无力患者,验证10条目患者报告结局量表OMGRate-q。探索性因子分析显示上睑下垂条目与复视条目为独立因子,复视子量表重测信度高(组内相关系数=0.95),上睑下垂条目信度良好(加权κ=0.56),与其它重症肌无力量表相关性中至高度。

要点

  • OMGRate-q为眼肌型重症肌无力特异性患者报告结局量表,复视子量表重测信度高(组内相关系数=0.95)。
  • 上睑下垂条目与复视条目为独立因子,上睑下垂条目信度良好(加权κ=0.56)。
  • 量表完成时间80.7(±45.2)秒,96.2%(125/130)参与者认为长度可接受。

核心结论

  • OMGRate-q是有效且可靠的眼肌型重症肌无力特异性患者报告结局量表,可用于促进以患者为中心的研究和照护。
  • OMGRate-q侧重复视对视觉功能的影响,以上睑下垂单一独立条目测量上睑下垂。
  • 未来需研究确定OMGRate-q对疾病状态变化的反应性,以及如何在该量表中增加上睑下垂测量或是否需要单独测量。

研究设计与样本

  • 前瞻性研究,纳入3个医疗中心18岁及以上眼肌型重症肌无力患者,时间为2022年1月至2023年10月。
  • 共纳入134例患者,其中女性45例(33.6%),白人99例(73.9%),中位年龄64.6岁(四分位距52.6-73.9岁)。
  • 施测10条目OMGRate-q,采用探索性因子分析及Andrich评定量表模型拟合,剔除拟合不佳条目后重新拟合模型。
  • 估计潜分数(theta),通过重复测量建立重测信度,并测量与其它重症肌无力患者报告结局量表的相关性。

主要发现

  • 一个上睑下垂相关条目显示显著的条目-特质偏差(p < 0.001),作为独立因子保留,与其余复视相关条目分开。
  • 排除该条目后,无拟合不佳条目。
  • 复视量表theta估计范围为-3.47至5.51,中位数=-0.53(四分位距-2.33,0.72)。
  • OMGRate-q复视子量表重测信度高(组内相关系数=0.95 [95% CI 0.90-0.98]),上睑下垂条目信度良好(加权κ=0.56)。
  • 3个中心间OMGRate-q复视子量表评分或上睑下垂条目无显著差异(复视p = 0.44;上睑下垂p = 0.32)。

关键数值与推荐

  • OMGRate-q复视子量表重测信度组内相关系数=0.95(95% CI 0.90-0.98)。
  • 上睑下垂条目重测信度加权κ=0.56。
  • 3中心间复视子量表评分比较p = 0.44,上睑下垂条目比较p = 0.32。
  • 与重症肌无力生活质量15问卷相关:复视r = 0.68(p < 0.001),上睑下垂r = 0.48(p < 0.001)。
  • 与重症肌无力损害指数相关:复视r = 0.76(p < 0.001),上睑下垂r = 0.77(p < 0.001)。

临床怎么用

  • OMGRate-q是有效且可靠的眼肌型重症肌无力特异性患者报告结局量表,可用于促进以患者为中心的研究和照护。
  • 作者指出OMGRate-q侧重复视对视觉功能的影响,以上睑下垂单一独立条目测量上睑下垂。
  • 作者指出未来需研究确定OMGRate-q对疾病状态变化的反应性,以及如何在该量表中增加上睑下垂测量或是否需要单独测量。

局限性

  • OMGRate-q侧重复视对视觉功能的影响,以上睑下垂单一独立条目测量上睑下垂。
  • 未来需研究确定OMGRate-q对疾病状态变化的反应性。
  • 未来需研究如何在该量表中增加上睑下垂测量或是否需要单独测量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Ocular myasthenia gravis (OMG) causes disabling ocular symptoms of ptosis and diplopia, but a validated disease-specific patient-reported outcome measure (PROM) has not been reported. We sought to validate a novel PROM for OMG, OMG Rating Scale Questionnaire (OMGRate-q), as a measure of visual functioning to support patient-centered care. METHODS: This was a prospective study of patients aged 18 years and older with OMG receiving care at 3 medical centers (January 2022-October 2023). The 10-item OMGRate-q was administered, and response data were analyzed using exploratory factor analysis followed by Andrich rating scale model fitting. Poorly fitting items were eliminated, and the model was refit to produce the final items, item locations, and thresholds. Latent scores (theta) were estimated, test-retest reliability was established with repeat measures, and correlation with other myasthenia gravis PROMs was measured. RESULTS: Of the 134 patients included in the study, 45 (33.6%) were women, 99 (73.9%) were White, and the median age (interquartile range [IQR]) was 64.6 years (52.6-73.9 years). A ptosis-related item showed significant item-trait deviation (p < 0.001) and was kept as a separate factor from the remaining diplopia-related items. After excluding this item, there were no misfitting items. Theta estimation for the diplopia scale ranged from -3.47 to 5.51 with median = -0.53 (IQR -2.33, 0.72). Test-retest reliability of the OMGRate-q diplopia subscale was high (intraclass correlation coefficient = 0.95 [95% CI 0.90-0.98]) and of the ptosis item was good (weighted κ = 0.56). No significant differences were observed in OMGRate-q diplopia subscale scores or the ptosis item between the 3 sites (diplopia p = 0.44; ptosis p = 0.32). OMGRate-q scores were moderately to highly correlated with the Myasthenia Gravis Quality of Life 15 questionnaire (n = 122; diplopia: r = 0.68, p < 0.001; ptosis: r = 0.48, p < 0.001) and Myasthenia Gravis Impairment Index (n = 130; diplopia: r = 0.76, p < 0.001; ptosis: r = 0.77, p < 0.001). OMGRate-q length was acceptable to most participants (125/130 [96.2%]), and the questionnaire was completed in 80.7 (±45.2) seconds. DISCUSSION: The OMGRate-q is a valid and reliable disease-specific PROM for OMG that may be used to facilitate patient-centered research and care. However, the OMGRate-q emphasizes the impact of diplopia on visual functioning with a single separate item measuring ptosis. Future studies are needed to determine OMGRate-q responsiveness to disease-state changes and how to add measures of ptosis to this scale or whether a separate measure is needed.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Wong SH, Abuzaitoun R, Cornblath WT, et al. Multicenter Validation of the Ocular Myasthenia Gravis Rating Scale Questionnaire. Neurology. 2024. PMID: 39657098. doi:10.1212/WNL.0000000000210150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。